SynthesisCurrent oncology (Toronto, Ont.)2024

Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Nivolumab vs. Pembrolizumab in Resectable Non-Small Cell Lung Cancer: A Systematic Review.

Anastasia Papaporfyriou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.